News Releases

Year

04 Dec '20

Cortexyme’s Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer’s Disease Successfully Advances Past Interim Analysis

-- GAIN Trial passes futility analysis and will continue to 1-year endpoint following the independent Data Monitoring Committee recommendation; topline results expected on time in December 2021 -- -- Final study enrollment remains at 643; no sample size adjustment -- -- Conference call and webcast

PDF Version

12 Nov '20

Cortexyme Announces Third Quarter 2020 Financial Results and Provides Business Update

— GAIN Trial enrollment complete with 643 participants — GAIN Trial interim analysis on schedule to complete in December 2020 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 12, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering potential therapeutics

PDF Version

05 Nov '20

Cortexyme Presents an Update and Baseline Data from the Phase 2/3 GAIN Trial of Atuzaginstat at CTAD 2020, the Clinical Trials on Alzheimer’s Disease Conference

-- Data demonstrate that patients enrolled in the GAIN Trial have baseline biomarkers consistent with Alzheimer’s disease and potential responders to atuzaginstat -- -- Press release issued in advance of CTAD presentation as an SEC exemption to the embargo policy, granted by the conference’s

PDF Version

19 Oct '20

Cortexyme Announces Upcoming Data Presentations at November 2020 Conferences

-- Oral presentation at Clinical Trials on Alzheimer's Disease 2020 will include baseline characteristics of the Phase 2/3 GAIN Trial ahead of planned interim analysis expected to occur before year-end 2020 -- -- Poster at Society for Immunotherapy of Cancer Annual Meeting evaluates the

PDF Version

24 Sep '20

Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 Patients

- Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 24, 2020-- Cortexyme, Inc. (Nasdaq: CRTX) today announced that its GAIN Trial for Alzheimer’s disease (AD) has exceeded its enrollment target of 570 patients.

PDF Version

09 Sep '20

Cortexyme to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

-- Presentation to be webcast on Cortexyme’s website -- SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 9, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey

PDF Version

27 Aug '20

Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office

- New U.S. Patent No. 10,730,826 provides additional composition of matter protection for atuzaginstat (COR388) - The '826 patent extends the patent term for atuzaginstat to 2037, with a possible patent term extension of up to an additional five years SOUTH SAN FRANCISCO, Calif.

PDF Version

17 Aug '20

Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business Update

— GAIN Trial enrollment on track to complete in Q4 2020 — GAIN Trial interim analysis on schedule to complete by year end 2020 — Clinical pipeline expansion anticipated in 2021 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 17, 2020-- Cortexyme, Inc.

PDF Version

14 Aug '20

Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Reached Enrollment Milestone of 500 Patients

- Open label extension is currently active for GAIN Trial completers in the United States with robust conversion of eligible patients - Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 14, 2020-- Cortexyme, Inc.

PDF Version

06 Aug '20

Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020

Presentations to be webcast on Cortexyme’s website SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 6, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 29